Show simple item record

dc.contributor.advisorGodoy, German Fabianspa
dc.contributor.authorRojas, Juan Pablo
dc.contributor.authorGodoy, German Fabian
dc.coverage.spatialMedicinaspa
dc.date.accessioned2020-06-18T12:16:52Z
dc.date.available2020-06-18T12:16:52Z
dc.date.issued2019-06-20
dc.identifier.urihttp://hdl.handle.net/10654/35933
dc.description.abstractProblema: El pilar del tratamiento para los pacientes con cáncer metastásico de próstata es la terapia de supresión androgénica. Una vez la enfermedad progresa y se considera resistente a la castración. El dietilestilbestrol es uno de los medicamentos que ha sido empleado en el tratamiento de los pacientes con cáncer de próstata metastásico resistente a la castración (CPMRC) demostrando efectividad en cuanto a progresión de la enfermedad. La literatura con la que se cuenta sobre dietilestilbestrol es antigua, la gran mayoría de los estudios son retrospectivos, por lo que se necesita mas evidencia sobre esto. Objetivo: Describir la supervivencia libre de progresión en los pacientes del servicio de Urología Oncológica del Instituto Nacional de Cancerología con diagnóstico de CPMRC en tratamiento con dietilestilbestrol 1mg/día más ácido acetil salicílico 100 mg/día. También se valorará la supervivencia global y se hará una evaluación de la calidad de vida en esta población. Materiales y métodos: Se llevará a cabo un estudio observacional, descriptivo y prospectivo seleccionando pacientes con CPMRC, con estado funcional Eastern Cooperative Oncology Group (ECOG) menor de 3, adecuada función hepática, electro y ecocardiograma sin alteraciones y ecografía doppler venosa de miembros inferiores normal en quienes se haya definido tratamiento con dietilestilbestrol. Se excluirán los pacientes que tengan antecedentes de eventos tromboembólicos. Ese evaluará la respuesta de PSA, supervivencia libre de progresión y adicionalmente se aplicará el cuestionario de Functional Assessment of Chronic Illness Therapy system versión 4 (FACIT-P), para evaluar la calidad de vida. Impacto esperado: Este estudio dará información relevante de los pacientes del Instituto Nacional de Cancerología E.S.E. con cáncer metastásico de próstata resistente a la castración en los que se defina manejo con dietilestilbestrol y que podra ser aplicada a la población colombiana, ya que todos los estudios con los que se cuenta son realizados en instituciones de otros países y los datos son extrapolados a nuestros población. Así Mismo, será útil para la generación de una base de datos que dará pie a futuras investigaciones y producirá nuevo conocimiento.spa
dc.formatpdfspa
dc.format.mimetypeapplication/pdfspa
dc.language.isospaspa
dc.language.isospaspa
dc.publisherUniversidad Militar Nueva Granadaspa
dc.rightsDerechos Reservados - Universidad Militar Nueva Granada, 2020spa
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.5/co/spa
dc.titleSupervivencia e impacto en la calidad de vida, del uso del dietilestilbestrol en los pacientes con cáncer metastásico de próstata resistente a la castraciónspa
dc.typeinfo:eu-repo/semantics/bachelorThesisspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.publisher.departmentFacultad de Medicinaspa
dc.type.localTrabajo de gradospa
dc.description.abstractenglishProblem: The mainstay of treatment for patients with metastatic prostate cancer is suppression therapy Androgenic Once the disease progresses and is considered resistant to castration. Diethylstilbestrol is one of the medications that has been used in the treatment of patients with castration-resistant metastatic prostate cancer (CPMRC) demonstrating effectiveness in disease progression. The literature on diethylstilbestrol is old, the vast majority of the studies are retrospective, so more evidence is needed on this. Objective: Describe progression-free survival in patients of the Oncology Urology Department of National Cancer Institute with diagnosis of CPMRC in treatment with diethylstilbestrol 1mg / day more acetylsalicylic acid 100 mg / day. The overall survival will also be assessed and an evaluation of the quality of life in this population. Materials and methods: An observational, descriptive and prospective study will be carried out by selecting CPMRC patients, with Eastern Cooperative Oncology Group (ECOG) functional status less than 3, adequate liver function, electro and echocardiography without alterations and venous doppler ultrasound of limbs lower normal in those who have defined treatment with diethylstilbestrol. Patients who have a history of thromboembolic events. That will evaluate the PSA response, survival free of progression and additionally the Functional Assessment of Chronic Illness Therapy questionnaire will be applied system version 4 (FACIT-P), to evaluate the quality of life. Expected impact: This study will give relevant information of the patients of the National Institute of Cancerology E.S.E. with metastatic castration-resistant prostate cancer in which management is defined with diethylstilbestrol and that could be applied to the Colombian population, since all the studies with which It counts are made in institutions of other countries and the data is extrapolated to our population. So It will be useful for the generation of a database that will lead to future research and produce new knowledge.eng
dc.title.translatedSurvival and impact on the quality of life, of the use of diethylstilbestrol in patients with castration resistant metastatic prostate cancerspa
dc.subject.keywordsdiethylstilbestrolspa
dc.subject.keywordsmetastatic castration-resistant prostate cancerspa
dc.publisher.programUrología Oncológicaspa
dc.creator.degreenameEspecialista en Urología Oncológicaspa
dc.subject.decsENFERMOS DE CANCER-REHABILITACION
dc.subject.decsPROSTATA-CANCER
dc.subject.decsNEOPLASMAS DE LA PROSTATA
dc.contributor.corporatenameGerman Fabian Godoyspa
dc.description.degreelevelEspecializaciónspa
dc.publisher.facultyMedicina y Ciencias de la Salud - Urología Oncológicaspa
dc.type.dcmi-type-vocabularyTextspa
dc.type.versioninfo:eu-repo/semantics/acceptedVersionspa
dc.rights.creativecommonsAtribución-NoComercial-SinDerivadasspa
dc.relation.referencesFerlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0. Cancer incidence and mortality worldwide. IARC cancer base no. 11. Lyon, France: International Agency for Research on Cancer; 2013.spa
dc.relation.referencesBosset PO, Albiges L, Seisen T, De la Motte Rouge T, Phé V, Bitker MO, et al. Current role of diethylstilbestrol in the management of advanced prostate cancer. BJU International. 2012;110, E826–9.spa
dc.relation.referencesHuggins C, Hodges CV: Studies on prostatic cancer II: the effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941;43:209–23.spa
dc.relation.referencesScher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castrationresistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016 Apr 20;34(12):1402-18.spa
dc.relation.referencesCrawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-24.spa
dc.relation.referencesEisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339:1036-42.spa
dc.relation.referencesMohler JL, Gregory CW, Ford OH, Kim D, Weaver CM, Petrusz P, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10:440-8.spa
dc.relation.referencesChen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9.spa
dc.relation.referencesSchmitt B, Wilt TJ, Schellhammer PF, DeMasi V, Sartor O, Crawford ED, et al. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology 2001;57:727-32.spa
dc.relation.referencesScherr DS, Pitts WR. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cáncer. J Urol. 2003;170:1703–8.spa
dc.relation.referencesAggarwal R, Weinberg V, Small EJ, Oh W, Rushakoff R, Ryan CJ. The Mechanism of Action of Estrogen in Castration-Resistant Prostate Cancer: Clues from hormone levels. Clin Genitourin Cancer. 2009;7:E71-6.spa
dc.relation.referencesKikuchi E, Nakashima J, Horiguchi Y, Oya M, Ohigashi T, Murai M. Enhancement of diethylstilbestrol induced cytotoxicity by bcl-2 antisense oligodeoxynucleotides and a glutathione depletor for prostate cáncer. J Urol. 2003;169:730–4.spa
dc.relation.referencesByar DP. Treatment of prostatic cancer: studies by the veterans administration cooperative urological research group. Bull. N. Y. Acad. Med. 1972;48:751-66.spa
dc.relation.referencesMalkowicz SB. The role of diethylstilbestrol in the treatment of prostate cancer. Urology. 2001;58: 108–13.spa
dc.relation.referencesRosenbaum E, Wygoda M, Gips M. Diethylstilbestrol is an active agent in prostate cancer patients after failure to complete androgen blockade. J Clin Oncol 2000;19:349a.spa
dc.relation.referencesClemons J, Glodé LM, Gao D, Flaig TW. Low-dose diethylstilbestrol for the treatment of advanced prostate cancer. Urol Oncol. 2013;31:198–204.spa
dc.relation.referencesGrenader T, Plotkin Y, Gips M, Cherny N, Gabizon A. Diethylstilbestrol for the treatment of patients with castration-resistant prostate cancer: retrospective analysis of a single institution experience. Oncol reports. 2014;31:428-34.spa
dc.relation.referencesWilkins A, Shahidi M, Parker C, Gunapala R, Thomas K, Huddart R, et al. Diethylstilbestrol in castrationresistant prostate cancer. BJU International 2012;110:E727–35.spa
dc.relation.referencesShamash J, Powles T, Sarker SJ, Protheroe A, Mithal N, Mills R, et al. A multicentre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol. Br J Cancer. 2011;104:620-8.spa
dc.relation.referencesTuro R, Tan K, Thygesen H, Sundaram SK, Chahal R, Prescott S, et al. Diethylstilboestrol (1 mg) in the management of castration-resistant prostate cancer. Urol Int. 2015;94(3):307-12.spa
dc.relation.referencesRyan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, el al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138-48spa
dc.relation.referencesBeer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg TN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424-33.spa
dc.relation.referencesParker C, Nilson S, Heinrich D, Helle SI, O´Sullivan JM, Fossá FD, et al. Alpha Emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213-23.spa
dc.relation.referencesFleiss JL, Levin B, Paik MC. Statistical Methods for Rates and Proportions. 3ed ed. New York: John Wiley & Sons; 2003.spa
dc.relation.referencesNewcombe RG. Two-Sided Confidence Intervals for the Single Proportion: Comparison of Seven Methods. Statist. Med. 1998;17:857-72.spa
dc.relation.referencesBallesteros M, Sanchez R, Merchán B, Varela R. Estudio de la estructura factorial de la escala de calidad de vida FACIT-P para los pacientes con cáncer de próstata. Rev Colomb Cancerol 2012;3:162-9.spa
dc.relation.referencesNishino N, Jagannathan JP, Ramaiya NH, Van den Abeele. Revised RECIST Guideline Version 1.1: What Oncologists Want to Know and What Radiologists Need to Know. AJR 2010;195:281–9.spa
dc.relation.referencesCulig M, Leppée M. From morisky to hill-bone; self-reports scales for measuring adherence to medication. Coll. Antropol. 2014;1:55–62.spa
dc.relation.referencesKantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422 (2010).spa
dc.relation.referencesde Bono, J. S. et al. Abiraterone and Increased Survival in Metastatic Prostate Cancer. N. Engl. J. Med. 364, 1995-2005 (2011).spa
dc.relation.referencesScher HI, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187-97.spa
dc.relation.referencesMeza JEG, Varela R, Ramírez A. Eficacia y seguridad del dietiletilbestrol, en el tratamiento del cáncer de próstata resistente a la castración. 27(1):6.spa
dc.subject.proposalcáncer de próstata metastásicospa
dc.subject.proposaldietilestilbestrolspa
dc.subject.proposalEnfermos de cancerspa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Derechos Reservados - Universidad Militar Nueva Granada, 2020
Except where otherwise noted, this item's license is described as Derechos Reservados - Universidad Militar Nueva Granada, 2020